Advertisement
< Advance Online Publication

Tegaderm™ CHG dressing significantly improves catheter-related infection rate in hemodialysis patients

Tegaderm™ CHG dressing significantly improves catheter-related infection rate in hemodialysis patients

Post author correction

Article Type: ORIGINAL RESEARCH ARTICLE

Article Subject: Dialysis

DOI:10.5301/jva.5000596

Authors

Marco Righetti, Nicola Palmieri, Oscar Bracchi, Mario Prencipe, Elena Bruschetta, Francesca Colombo, Irene Brenna, Francesca Stefani, Karen Amar, Alfio Scalia, Ferruccio Conte

Abstract

Catheter-related infections are an important clinical problem in maintenance hemodialysis patients. Catheter-related bloodstream infections have a negative effect on survival, hospitalization and cost of care. Tegaderm™ chlorhexidine gluconate (CHG) dressing may be useful to reduce catheter-related infection rates.

We performed a study to assess the efficacy of Tegaderm™ CHG dressing for reducing catheter-related infections. We designed a prospective randomized cross-over study with a scheme of two treatments, Tegaderm™ CHG dressing versus standard dressing, and two periods of six months. Catheter-related infection rate was the primary outcome. We enrolled 59 prevalent hemodialysis patients.

Catheter-related infection rate per 1000 catheter days was reduced from 1.21 in patients using standard dressing to 0.28 in patients with Tegaderm™ CHG dressing (p = 0.02). Catheter-related bloodstream infection rate per 1000 catheter days was equal to 0.09 in patients with Tegaderm™ CHG dressing versus 0.65 in patients with standard dressing (p = 0.05). Annual total healthcare costs for catheter-related bloodstream infections were estimated equal to EUR62,459 versus EUR300,399, respectively, for patients with Tegaderm™ CHG versus standard dressing.

This is the first prospective study to show that Tegaderm™ CHG dressing significantly reduces catheter-related infection rates in hemodialysis patients.

Article History

  • • Accepted on 12/06/2016
  • • Available online on 01/08/2016

Disclosures

Financial support: No grants or funding have been received related to this study.
Conflict of interest: None of the authors has financial interest related to this study to disclose.
Meeting presentation: Part of this paper was accepted and presented as an oral communication at the ERA-EDTA Congress, London, May 2015.

This article is available as full text PDF.

  • If you are a Subscriber, please log in now.

  • Article price: Eur 36,00
  • You will be granted access to the article for 72 hours and you will be able to download any format (PDF or ePUB). The article will be available in your login area under "My PayPerView". You will need to register a new account (unless you already own an account with this journal), and you will be guided through our online shop. Online purchases are paid by Credit Card through PayPal.
  • If you are not a Subscriber you may:
  • Subscribe to this journal
  • Unlimited access to all our archives, 24 hour a day, every day of the week.

Authors

  • Righetti, Marco [PubMed] [Google Scholar] , * Corresponding Author (righettim@hotmail.com)
  • Palmieri, Nicola [PubMed] [Google Scholar]
  • Bracchi, Oscar [PubMed] [Google Scholar]
  • Prencipe, Mario [PubMed] [Google Scholar]
  • Bruschetta, Elena [PubMed] [Google Scholar]
  • Colombo, Francesca [PubMed] [Google Scholar]
  • Brenna, Irene [PubMed] [Google Scholar]
  • Stefani, Francesca [PubMed] [Google Scholar]
  • Amar, Karen [PubMed] [Google Scholar]
  • Scalia, Alfio [PubMed] [Google Scholar]
  • Conte, Ferruccio [PubMed] [Google Scholar]

Affiliations

  • Renal Unit, Uboldo Hospital, Cernusco s/N, Milan - Italy

Article usage statistics

The blue line displays unique views in the time frame indicated.
The yellow line displays unique downloads.
Views and downloads are counted only once per session.

No supplementary material is available for this article.